nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—CYP1A2—Pentoxifylline—systemic scleroderma	0.0682	0.126	CbGbCtD
Fluvoxamine—CYP1A2—Leflunomide—systemic scleroderma	0.0651	0.12	CbGbCtD
Fluvoxamine—ABCB1—Lisinopril—systemic scleroderma	0.0597	0.11	CbGbCtD
Fluvoxamine—CYP2C9—Leflunomide—systemic scleroderma	0.0586	0.108	CbGbCtD
Fluvoxamine—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.054	0.0996	CbGbCtD
Fluvoxamine—ABCB1—Captopril—systemic scleroderma	0.0447	0.0823	CbGbCtD
Fluvoxamine—CYP2D6—Captopril—systemic scleroderma	0.0421	0.0776	CbGbCtD
Fluvoxamine—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0352	0.0648	CbGbCtD
Fluvoxamine—CYP2C19—Prednisone—systemic scleroderma	0.0348	0.0642	CbGbCtD
Fluvoxamine—ABCB1—Prednisone—systemic scleroderma	0.0281	0.0518	CbGbCtD
Fluvoxamine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0211	0.0388	CbGbCtD
Fluvoxamine—CYP3A4—Prednisone—systemic scleroderma	0.0168	0.031	CbGbCtD
Fluvoxamine—ABCB1—Methotrexate—systemic scleroderma	0.0141	0.026	CbGbCtD
Fluvoxamine—CYP2C9—cardial valve—systemic scleroderma	0.00465	0.452	CbGeAlD
Fluvoxamine—SIGMAR1—smooth muscle tissue—systemic scleroderma	0.000394	0.0383	CbGeAlD
Fluvoxamine—SLC6A4—digestive system—systemic scleroderma	0.000313	0.0305	CbGeAlD
Fluvoxamine—SIGMAR1—tendon—systemic scleroderma	0.000296	0.0288	CbGeAlD
Fluvoxamine—ABCB1—blood vessel—systemic scleroderma	0.000294	0.0285	CbGeAlD
Fluvoxamine—SLC6A3—lung—systemic scleroderma	0.000286	0.0278	CbGeAlD
Fluvoxamine—SLC6A4—lung—systemic scleroderma	0.000262	0.0254	CbGeAlD
Fluvoxamine—CYP1A1—skin of body—systemic scleroderma	0.000262	0.0254	CbGeAlD
Fluvoxamine—SIGMAR1—lung—systemic scleroderma	0.00026	0.0253	CbGeAlD
Fluvoxamine—CYP2C19—digestive system—systemic scleroderma	0.00026	0.0252	CbGeAlD
Fluvoxamine—CYP2B6—skin of body—systemic scleroderma	0.000254	0.0247	CbGeAlD
Fluvoxamine—CYP1A2—digestive system—systemic scleroderma	0.000212	0.0206	CbGeAlD
Fluvoxamine—CYP1A1—digestive system—systemic scleroderma	0.000209	0.0203	CbGeAlD
Fluvoxamine—CYP3A5—digestive system—systemic scleroderma	0.000205	0.0199	CbGeAlD
Fluvoxamine—CYP2B6—digestive system—systemic scleroderma	0.000203	0.0198	CbGeAlD
Fluvoxamine—CYP2C9—digestive system—systemic scleroderma	0.000201	0.0196	CbGeAlD
Fluvoxamine—CYP2E1—digestive system—systemic scleroderma	0.000191	0.0185	CbGeAlD
Fluvoxamine—CYP2E1—tendon—systemic scleroderma	0.000182	0.0177	CbGeAlD
Fluvoxamine—CYP1A2—lung—systemic scleroderma	0.000177	0.0172	CbGeAlD
Fluvoxamine—CYP1A1—lung—systemic scleroderma	0.000175	0.017	CbGeAlD
Fluvoxamine—CYP3A5—lung—systemic scleroderma	0.000171	0.0166	CbGeAlD
Fluvoxamine—CYP2B6—lung—systemic scleroderma	0.00017	0.0165	CbGeAlD
Fluvoxamine—CYP2E1—lung—systemic scleroderma	0.000159	0.0155	CbGeAlD
Fluvoxamine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000158	0.000354	CcSEcCtD
Fluvoxamine—Urticaria—Leflunomide—systemic scleroderma	0.000158	0.000353	CcSEcCtD
Fluvoxamine—Body temperature increased—Leflunomide—systemic scleroderma	0.000157	0.000351	CcSEcCtD
Fluvoxamine—Abdominal pain—Leflunomide—systemic scleroderma	0.000157	0.000351	CcSEcCtD
Fluvoxamine—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000157	0.00035	CcSEcCtD
Fluvoxamine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000156	0.000349	CcSEcCtD
Fluvoxamine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000156	0.000349	CcSEcCtD
Fluvoxamine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000156	0.000349	CcSEcCtD
Fluvoxamine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000156	0.000349	CcSEcCtD
Fluvoxamine—Myocardial infarction—Prednisone—systemic scleroderma	0.000156	0.000348	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000156	0.000348	CcSEcCtD
Fluvoxamine—Breast disorder—Methotrexate—systemic scleroderma	0.000156	0.000348	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000156	0.000348	CcSEcCtD
Fluvoxamine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000156	0.000348	CcSEcCtD
Fluvoxamine—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000155	0.000347	CcSEcCtD
Fluvoxamine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000155	0.000347	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000155	0.000347	CcSEcCtD
Fluvoxamine—Insomnia—Lisinopril—systemic scleroderma	0.000154	0.000345	CcSEcCtD
Fluvoxamine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000345	CcSEcCtD
Fluvoxamine—CYP3A4—digestive system—systemic scleroderma	0.000154	0.0149	CbGeAlD
Fluvoxamine—Paraesthesia—Lisinopril—systemic scleroderma	0.000153	0.000343	CcSEcCtD
Fluvoxamine—Vomiting—Captopril—systemic scleroderma	0.000153	0.000343	CcSEcCtD
Fluvoxamine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000153	0.000341	CcSEcCtD
Fluvoxamine—Dyspnoea—Lisinopril—systemic scleroderma	0.000152	0.00034	CcSEcCtD
Fluvoxamine—Rash—Captopril—systemic scleroderma	0.000152	0.00034	CcSEcCtD
Fluvoxamine—Dermatitis—Captopril—systemic scleroderma	0.000152	0.00034	CcSEcCtD
Fluvoxamine—Somnolence—Lisinopril—systemic scleroderma	0.000152	0.000339	CcSEcCtD
Fluvoxamine—CYP2D6—digestive system—systemic scleroderma	0.000151	0.0147	CbGeAlD
Fluvoxamine—Headache—Captopril—systemic scleroderma	0.000151	0.000338	CcSEcCtD
Fluvoxamine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000151	0.000337	CcSEcCtD
Fluvoxamine—Dyspepsia—Lisinopril—systemic scleroderma	0.00015	0.000336	CcSEcCtD
Fluvoxamine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00015	0.000335	CcSEcCtD
Fluvoxamine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00015	0.000335	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00015	0.000335	CcSEcCtD
Fluvoxamine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00015	0.000335	CcSEcCtD
Fluvoxamine—Asthma—Methotrexate—systemic scleroderma	0.000149	0.000333	CcSEcCtD
Fluvoxamine—Infection—Mycophenolate mofetil—systemic scleroderma	0.000149	0.000332	CcSEcCtD
Fluvoxamine—Decreased appetite—Lisinopril—systemic scleroderma	0.000148	0.000332	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000147	0.00033	CcSEcCtD
Fluvoxamine—Fatigue—Lisinopril—systemic scleroderma	0.000147	0.000329	CcSEcCtD
Fluvoxamine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000329	CcSEcCtD
Fluvoxamine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000328	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000328	CcSEcCtD
Fluvoxamine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000146	0.000327	CcSEcCtD
Fluvoxamine—Pancreatitis—Methotrexate—systemic scleroderma	0.000146	0.000327	CcSEcCtD
Fluvoxamine—Constipation—Lisinopril—systemic scleroderma	0.000146	0.000326	CcSEcCtD
Fluvoxamine—Pain—Lisinopril—systemic scleroderma	0.000146	0.000326	CcSEcCtD
Fluvoxamine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000326	CcSEcCtD
Fluvoxamine—Bradycardia—Prednisone—systemic scleroderma	0.000145	0.000325	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000145	0.000323	CcSEcCtD
Fluvoxamine—Diarrhoea—Azathioprine—systemic scleroderma	0.000144	0.000322	CcSEcCtD
Fluvoxamine—Haemoglobin—Prednisone—systemic scleroderma	0.000143	0.000321	CcSEcCtD
Fluvoxamine—Nausea—Captopril—systemic scleroderma	0.000143	0.00032	CcSEcCtD
Fluvoxamine—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000143	0.000319	CcSEcCtD
Fluvoxamine—Haemorrhage—Prednisone—systemic scleroderma	0.000143	0.000319	CcSEcCtD
Fluvoxamine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000143	0.000319	CcSEcCtD
Fluvoxamine—Asthenia—Leflunomide—systemic scleroderma	0.000143	0.000319	CcSEcCtD
Fluvoxamine—Hallucination—Prednisone—systemic scleroderma	0.000142	0.000318	CcSEcCtD
Fluvoxamine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000141	0.000315	CcSEcCtD
Fluvoxamine—Pruritus—Leflunomide—systemic scleroderma	0.000141	0.000314	CcSEcCtD
Fluvoxamine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00014	0.000313	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00014	0.000312	CcSEcCtD
Fluvoxamine—Dysuria—Methotrexate—systemic scleroderma	0.000139	0.000312	CcSEcCtD
Fluvoxamine—Dizziness—Azathioprine—systemic scleroderma	0.000139	0.000311	CcSEcCtD
Fluvoxamine—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000139	0.00031	CcSEcCtD
Fluvoxamine—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000137	0.000307	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000136	0.000305	CcSEcCtD
Fluvoxamine—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000136	0.000304	CcSEcCtD
Fluvoxamine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000136	0.000304	CcSEcCtD
Fluvoxamine—Diarrhoea—Leflunomide—systemic scleroderma	0.000136	0.000304	CcSEcCtD
Fluvoxamine—Urticaria—Lisinopril—systemic scleroderma	0.000136	0.000303	CcSEcCtD
Fluvoxamine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000135	0.000303	CcSEcCtD
Fluvoxamine—Abdominal pain—Lisinopril—systemic scleroderma	0.000135	0.000302	CcSEcCtD
Fluvoxamine—Body temperature increased—Lisinopril—systemic scleroderma	0.000135	0.000302	CcSEcCtD
Fluvoxamine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000134	0.0003	CcSEcCtD
Fluvoxamine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000134	0.0003	CcSEcCtD
Fluvoxamine—Vomiting—Azathioprine—systemic scleroderma	0.000134	0.000299	CcSEcCtD
Fluvoxamine—Pneumonia—Methotrexate—systemic scleroderma	0.000134	0.000299	CcSEcCtD
Fluvoxamine—Eye disorder—Prednisone—systemic scleroderma	0.000133	0.000298	CcSEcCtD
Fluvoxamine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000298	CcSEcCtD
Fluvoxamine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000297	CcSEcCtD
Fluvoxamine—Drowsiness—Methotrexate—systemic scleroderma	0.000133	0.000297	CcSEcCtD
Fluvoxamine—Rash—Azathioprine—systemic scleroderma	0.000133	0.000297	CcSEcCtD
Fluvoxamine—Dermatitis—Azathioprine—systemic scleroderma	0.000133	0.000296	CcSEcCtD
Fluvoxamine—Depression—Methotrexate—systemic scleroderma	0.000133	0.000296	CcSEcCtD
Fluvoxamine—Headache—Azathioprine—systemic scleroderma	0.000132	0.000295	CcSEcCtD
Fluvoxamine—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000132	0.000295	CcSEcCtD
Fluvoxamine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000294	CcSEcCtD
Fluvoxamine—Dizziness—Leflunomide—systemic scleroderma	0.000131	0.000294	CcSEcCtD
Fluvoxamine—Renal failure—Methotrexate—systemic scleroderma	0.000131	0.000292	CcSEcCtD
Fluvoxamine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00013	0.000291	CcSEcCtD
Fluvoxamine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00013	0.00029	CcSEcCtD
Fluvoxamine—Stomatitis—Methotrexate—systemic scleroderma	0.00013	0.00029	CcSEcCtD
Fluvoxamine—Angiopathy—Prednisone—systemic scleroderma	0.00013	0.00029	CcSEcCtD
Fluvoxamine—Conjunctivitis—Methotrexate—systemic scleroderma	0.000129	0.000289	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000129	0.000289	CcSEcCtD
Fluvoxamine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000128	0.000286	CcSEcCtD
Fluvoxamine—Pain—Mycophenolate mofetil—systemic scleroderma	0.000128	0.000286	CcSEcCtD
Fluvoxamine—Arrhythmia—Prednisone—systemic scleroderma	0.000128	0.000285	CcSEcCtD
Fluvoxamine—Sweating—Methotrexate—systemic scleroderma	0.000127	0.000285	CcSEcCtD
Fluvoxamine—Haematuria—Methotrexate—systemic scleroderma	0.000127	0.000283	CcSEcCtD
Fluvoxamine—Vomiting—Leflunomide—systemic scleroderma	0.000126	0.000283	CcSEcCtD
Fluvoxamine—Alopecia—Prednisone—systemic scleroderma	0.000126	0.000282	CcSEcCtD
Fluvoxamine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000126	0.000281	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000126	0.000281	CcSEcCtD
Fluvoxamine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000125	0.00028	CcSEcCtD
Fluvoxamine—Epistaxis—Methotrexate—systemic scleroderma	0.000125	0.00028	CcSEcCtD
Fluvoxamine—Rash—Leflunomide—systemic scleroderma	0.000125	0.00028	CcSEcCtD
Fluvoxamine—Dermatitis—Leflunomide—systemic scleroderma	0.000125	0.00028	CcSEcCtD
Fluvoxamine—Mental disorder—Prednisone—systemic scleroderma	0.000125	0.00028	CcSEcCtD
Fluvoxamine—Nausea—Azathioprine—systemic scleroderma	0.000125	0.000279	CcSEcCtD
Fluvoxamine—Headache—Leflunomide—systemic scleroderma	0.000125	0.000278	CcSEcCtD
Fluvoxamine—Malnutrition—Prednisone—systemic scleroderma	0.000124	0.000278	CcSEcCtD
Fluvoxamine—Agranulocytosis—Methotrexate—systemic scleroderma	0.000124	0.000277	CcSEcCtD
Fluvoxamine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000276	CcSEcCtD
Fluvoxamine—Asthenia—Lisinopril—systemic scleroderma	0.000123	0.000274	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000274	CcSEcCtD
Fluvoxamine—Pruritus—Lisinopril—systemic scleroderma	0.000121	0.00027	CcSEcCtD
Fluvoxamine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000121	0.00027	CcSEcCtD
Fluvoxamine—Haemoglobin—Methotrexate—systemic scleroderma	0.00012	0.000268	CcSEcCtD
Fluvoxamine—Rash—Mycophenolic acid—systemic scleroderma	0.00012	0.000267	CcSEcCtD
Fluvoxamine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000119	0.000267	CcSEcCtD
Fluvoxamine—Haemorrhage—Methotrexate—systemic scleroderma	0.000119	0.000267	CcSEcCtD
Fluvoxamine—Hepatitis—Methotrexate—systemic scleroderma	0.000119	0.000267	CcSEcCtD
Fluvoxamine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000266	CcSEcCtD
Fluvoxamine—Headache—Mycophenolic acid—systemic scleroderma	0.000119	0.000266	CcSEcCtD
Fluvoxamine—Pharyngitis—Methotrexate—systemic scleroderma	0.000118	0.000265	CcSEcCtD
Fluvoxamine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000264	CcSEcCtD
Fluvoxamine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000264	CcSEcCtD
Fluvoxamine—Nausea—Leflunomide—systemic scleroderma	0.000118	0.000264	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000118	0.000263	CcSEcCtD
Fluvoxamine—Vision blurred—Prednisone—systemic scleroderma	0.000117	0.000262	CcSEcCtD
Fluvoxamine—Urethral disorder—Methotrexate—systemic scleroderma	0.000117	0.000261	CcSEcCtD
Fluvoxamine—Diarrhoea—Lisinopril—systemic scleroderma	0.000117	0.000261	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Prednisone—systemic scleroderma	0.000115	0.000258	CcSEcCtD
Fluvoxamine—Visual impairment—Methotrexate—systemic scleroderma	0.000115	0.000257	CcSEcCtD
Fluvoxamine—Anaemia—Prednisone—systemic scleroderma	0.000115	0.000257	CcSEcCtD
Fluvoxamine—Agitation—Prednisone—systemic scleroderma	0.000114	0.000255	CcSEcCtD
Fluvoxamine—Angioedema—Prednisone—systemic scleroderma	0.000114	0.000254	CcSEcCtD
Fluvoxamine—Dizziness—Lisinopril—systemic scleroderma	0.000113	0.000252	CcSEcCtD
Fluvoxamine—Erythema multiforme—Methotrexate—systemic scleroderma	0.000113	0.000252	CcSEcCtD
Fluvoxamine—Nausea—Mycophenolic acid—systemic scleroderma	0.000113	0.000252	CcSEcCtD
Fluvoxamine—Malaise—Prednisone—systemic scleroderma	0.000112	0.000251	CcSEcCtD
Fluvoxamine—Vertigo—Prednisone—systemic scleroderma	0.000112	0.00025	CcSEcCtD
Fluvoxamine—Eye disorder—Methotrexate—systemic scleroderma	0.000111	0.000249	CcSEcCtD
Fluvoxamine—Syncope—Prednisone—systemic scleroderma	0.000111	0.000249	CcSEcCtD
Fluvoxamine—Tinnitus—Methotrexate—systemic scleroderma	0.000111	0.000249	CcSEcCtD
Fluvoxamine—Cardiac disorder—Methotrexate—systemic scleroderma	0.000111	0.000248	CcSEcCtD
Fluvoxamine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00011	0.000246	CcSEcCtD
Fluvoxamine—Loss of consciousness—Prednisone—systemic scleroderma	0.000109	0.000244	CcSEcCtD
Fluvoxamine—ABCB1—digestive system—systemic scleroderma	0.000109	0.0106	CbGeAlD
Fluvoxamine—Vomiting—Lisinopril—systemic scleroderma	0.000109	0.000243	CcSEcCtD
Fluvoxamine—Angiopathy—Methotrexate—systemic scleroderma	0.000108	0.000242	CcSEcCtD
Fluvoxamine—Rash—Lisinopril—systemic scleroderma	0.000108	0.000241	CcSEcCtD
Fluvoxamine—Convulsion—Prednisone—systemic scleroderma	0.000108	0.000241	CcSEcCtD
Fluvoxamine—Dermatitis—Lisinopril—systemic scleroderma	0.000108	0.000241	CcSEcCtD
Fluvoxamine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000107	0.00024	CcSEcCtD
Fluvoxamine—Hypertension—Prednisone—systemic scleroderma	0.000107	0.00024	CcSEcCtD
Fluvoxamine—Chills—Methotrexate—systemic scleroderma	0.000107	0.000239	CcSEcCtD
Fluvoxamine—Headache—Lisinopril—systemic scleroderma	0.000107	0.000239	CcSEcCtD
Fluvoxamine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000237	CcSEcCtD
Fluvoxamine—Arthralgia—Prednisone—systemic scleroderma	0.000106	0.000237	CcSEcCtD
Fluvoxamine—Myalgia—Prednisone—systemic scleroderma	0.000106	0.000237	CcSEcCtD
Fluvoxamine—Anxiety—Prednisone—systemic scleroderma	0.000105	0.000236	CcSEcCtD
Fluvoxamine—Alopecia—Methotrexate—systemic scleroderma	0.000105	0.000236	CcSEcCtD
Fluvoxamine—Discomfort—Prednisone—systemic scleroderma	0.000105	0.000234	CcSEcCtD
Fluvoxamine—Mental disorder—Methotrexate—systemic scleroderma	0.000105	0.000234	CcSEcCtD
Fluvoxamine—Malnutrition—Methotrexate—systemic scleroderma	0.000104	0.000232	CcSEcCtD
Fluvoxamine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000229	CcSEcCtD
Fluvoxamine—Dysgeusia—Methotrexate—systemic scleroderma	0.000102	0.000227	CcSEcCtD
Fluvoxamine—Nausea—Lisinopril—systemic scleroderma	0.000101	0.000227	CcSEcCtD
Fluvoxamine—Oedema—Prednisone—systemic scleroderma	0.000101	0.000227	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Prednisone—systemic scleroderma	0.000101	0.000227	CcSEcCtD
Fluvoxamine—Infection—Prednisone—systemic scleroderma	0.000101	0.000225	CcSEcCtD
Fluvoxamine—Back pain—Methotrexate—systemic scleroderma	0.0001	0.000225	CcSEcCtD
Fluvoxamine—Shock—Prednisone—systemic scleroderma	9.98e-05	0.000223	CcSEcCtD
Fluvoxamine—Nervous system disorder—Prednisone—systemic scleroderma	9.95e-05	0.000222	CcSEcCtD
Fluvoxamine—Tachycardia—Prednisone—systemic scleroderma	9.9e-05	0.000221	CcSEcCtD
Fluvoxamine—Dizziness—Mycophenolate mofetil—systemic scleroderma	9.89e-05	0.000221	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Prednisone—systemic scleroderma	9.8e-05	0.000219	CcSEcCtD
Fluvoxamine—Vision blurred—Methotrexate—systemic scleroderma	9.79e-05	0.000219	CcSEcCtD
Fluvoxamine—Anorexia—Prednisone—systemic scleroderma	9.67e-05	0.000216	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Methotrexate—systemic scleroderma	9.64e-05	0.000215	CcSEcCtD
Fluvoxamine—Anaemia—Methotrexate—systemic scleroderma	9.6e-05	0.000215	CcSEcCtD
Fluvoxamine—Vomiting—Mycophenolate mofetil—systemic scleroderma	9.51e-05	0.000213	CcSEcCtD
Fluvoxamine—Rash—Mycophenolate mofetil—systemic scleroderma	9.43e-05	0.000211	CcSEcCtD
Fluvoxamine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	9.43e-05	0.000211	CcSEcCtD
Fluvoxamine—Headache—Mycophenolate mofetil—systemic scleroderma	9.37e-05	0.00021	CcSEcCtD
Fluvoxamine—Malaise—Methotrexate—systemic scleroderma	9.37e-05	0.000209	CcSEcCtD
Fluvoxamine—Vertigo—Methotrexate—systemic scleroderma	9.33e-05	0.000209	CcSEcCtD
Fluvoxamine—Leukopenia—Methotrexate—systemic scleroderma	9.3e-05	0.000208	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	9.24e-05	0.000207	CcSEcCtD
Fluvoxamine—Insomnia—Prednisone—systemic scleroderma	9.17e-05	0.000205	CcSEcCtD
Fluvoxamine—Paraesthesia—Prednisone—systemic scleroderma	9.11e-05	0.000204	CcSEcCtD
Fluvoxamine—ABCB1—lung—systemic scleroderma	9.08e-05	0.00882	CbGeAlD
Fluvoxamine—Cough—Methotrexate—systemic scleroderma	9.06e-05	0.000203	CcSEcCtD
Fluvoxamine—Convulsion—Methotrexate—systemic scleroderma	9e-05	0.000201	CcSEcCtD
Fluvoxamine—Dyspepsia—Prednisone—systemic scleroderma	8.93e-05	0.0002	CcSEcCtD
Fluvoxamine—Nausea—Mycophenolate mofetil—systemic scleroderma	8.89e-05	0.000199	CcSEcCtD
Fluvoxamine—Chest pain—Methotrexate—systemic scleroderma	8.84e-05	0.000198	CcSEcCtD
Fluvoxamine—Myalgia—Methotrexate—systemic scleroderma	8.84e-05	0.000198	CcSEcCtD
Fluvoxamine—Arthralgia—Methotrexate—systemic scleroderma	8.84e-05	0.000198	CcSEcCtD
Fluvoxamine—Decreased appetite—Prednisone—systemic scleroderma	8.82e-05	0.000197	CcSEcCtD
Fluvoxamine—Fatigue—Prednisone—systemic scleroderma	8.74e-05	0.000195	CcSEcCtD
Fluvoxamine—Discomfort—Methotrexate—systemic scleroderma	8.74e-05	0.000195	CcSEcCtD
Fluvoxamine—Constipation—Prednisone—systemic scleroderma	8.67e-05	0.000194	CcSEcCtD
Fluvoxamine—Confusional state—Methotrexate—systemic scleroderma	8.55e-05	0.000191	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Methotrexate—systemic scleroderma	8.48e-05	0.00019	CcSEcCtD
Fluvoxamine—Infection—Methotrexate—systemic scleroderma	8.42e-05	0.000188	CcSEcCtD
Fluvoxamine—Feeling abnormal—Prednisone—systemic scleroderma	8.36e-05	0.000187	CcSEcCtD
Fluvoxamine—Nervous system disorder—Methotrexate—systemic scleroderma	8.31e-05	0.000186	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Methotrexate—systemic scleroderma	8.3e-05	0.000186	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Prednisone—systemic scleroderma	8.29e-05	0.000185	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Methotrexate—systemic scleroderma	8.19e-05	0.000183	CcSEcCtD
Fluvoxamine—Anorexia—Methotrexate—systemic scleroderma	8.08e-05	0.000181	CcSEcCtD
Fluvoxamine—Urticaria—Prednisone—systemic scleroderma	8.06e-05	0.00018	CcSEcCtD
Fluvoxamine—Abdominal pain—Prednisone—systemic scleroderma	8.02e-05	0.000179	CcSEcCtD
Fluvoxamine—Body temperature increased—Prednisone—systemic scleroderma	8.02e-05	0.000179	CcSEcCtD
Fluvoxamine—Hypotension—Methotrexate—systemic scleroderma	7.92e-05	0.000177	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	7.72e-05	0.000173	CcSEcCtD
Fluvoxamine—Insomnia—Methotrexate—systemic scleroderma	7.67e-05	0.000171	CcSEcCtD
Fluvoxamine—Paraesthesia—Methotrexate—systemic scleroderma	7.61e-05	0.00017	CcSEcCtD
Fluvoxamine—Dyspnoea—Methotrexate—systemic scleroderma	7.56e-05	0.000169	CcSEcCtD
Fluvoxamine—Somnolence—Methotrexate—systemic scleroderma	7.54e-05	0.000168	CcSEcCtD
Fluvoxamine—Hypersensitivity—Prednisone—systemic scleroderma	7.47e-05	0.000167	CcSEcCtD
Fluvoxamine—Dyspepsia—Methotrexate—systemic scleroderma	7.46e-05	0.000167	CcSEcCtD
Fluvoxamine—Decreased appetite—Methotrexate—systemic scleroderma	7.37e-05	0.000165	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	7.32e-05	0.000164	CcSEcCtD
Fluvoxamine—Fatigue—Methotrexate—systemic scleroderma	7.31e-05	0.000163	CcSEcCtD
Fluvoxamine—Asthenia—Prednisone—systemic scleroderma	7.28e-05	0.000163	CcSEcCtD
Fluvoxamine—Pain—Methotrexate—systemic scleroderma	7.25e-05	0.000162	CcSEcCtD
Fluvoxamine—Pruritus—Prednisone—systemic scleroderma	7.18e-05	0.00016	CcSEcCtD
Fluvoxamine—Feeling abnormal—Methotrexate—systemic scleroderma	6.98e-05	0.000156	CcSEcCtD
Fluvoxamine—Diarrhoea—Prednisone—systemic scleroderma	6.94e-05	0.000155	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Methotrexate—systemic scleroderma	6.93e-05	0.000155	CcSEcCtD
Fluvoxamine—Urticaria—Methotrexate—systemic scleroderma	6.73e-05	0.000151	CcSEcCtD
Fluvoxamine—Dizziness—Prednisone—systemic scleroderma	6.71e-05	0.00015	CcSEcCtD
Fluvoxamine—Abdominal pain—Methotrexate—systemic scleroderma	6.7e-05	0.00015	CcSEcCtD
Fluvoxamine—Body temperature increased—Methotrexate—systemic scleroderma	6.7e-05	0.00015	CcSEcCtD
Fluvoxamine—Vomiting—Prednisone—systemic scleroderma	6.45e-05	0.000144	CcSEcCtD
Fluvoxamine—Rash—Prednisone—systemic scleroderma	6.39e-05	0.000143	CcSEcCtD
Fluvoxamine—Dermatitis—Prednisone—systemic scleroderma	6.39e-05	0.000143	CcSEcCtD
Fluvoxamine—Headache—Prednisone—systemic scleroderma	6.35e-05	0.000142	CcSEcCtD
Fluvoxamine—Hypersensitivity—Methotrexate—systemic scleroderma	6.25e-05	0.00014	CcSEcCtD
Fluvoxamine—Asthenia—Methotrexate—systemic scleroderma	6.08e-05	0.000136	CcSEcCtD
Fluvoxamine—Nausea—Prednisone—systemic scleroderma	6.02e-05	0.000135	CcSEcCtD
Fluvoxamine—Pruritus—Methotrexate—systemic scleroderma	6e-05	0.000134	CcSEcCtD
Fluvoxamine—Diarrhoea—Methotrexate—systemic scleroderma	5.8e-05	0.00013	CcSEcCtD
Fluvoxamine—Dizziness—Methotrexate—systemic scleroderma	5.61e-05	0.000125	CcSEcCtD
Fluvoxamine—Vomiting—Methotrexate—systemic scleroderma	5.39e-05	0.00012	CcSEcCtD
Fluvoxamine—Rash—Methotrexate—systemic scleroderma	5.34e-05	0.000119	CcSEcCtD
Fluvoxamine—Dermatitis—Methotrexate—systemic scleroderma	5.34e-05	0.000119	CcSEcCtD
Fluvoxamine—Headache—Methotrexate—systemic scleroderma	5.31e-05	0.000119	CcSEcCtD
Fluvoxamine—Nausea—Methotrexate—systemic scleroderma	5.03e-05	0.000113	CcSEcCtD
